Trial
NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
Seagen Inc.
Condition
Adult Grade III Lymphomatoid Granulomatosis
Intervention
brentuximab vedotin
Why stopped
Lack of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-01